Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

  • Technology appraisal guidance
  • TA779
  • Published: 
Download guidance (PDF)

5 Recommendations for data collection

5.1 Proposals for further data collection in the Cancer Drugs Fund include further evidence on:

  • overall survival

  • progression-free survival

  • time to treatment discontinuation, and

  • the comparative effectiveness.